Intratio
Loading...
Skip to main content
Model output · Signal date 2026-10-16

Tuhura Biosciences, Inc./Nv (HURA) Stock Forecast Oct. 16, 2026

Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq

Follow Unlock full AI forecasts
Rating · 90D ▼ Bearish Exact rating locked
90-day forecast Sign up free to reveal
30-day forecast Alpha
Rank in coverage Bottom 35% of 5184 stocks scored
Rank correlation · 90D 30.0% Spearman, 357 dates
Market Cap $107M small-cap · #60 of 60 peers
Summary

Tuhura Biosciences, Inc./Nv (HURA) stock forecast summary

Our AI ranks Tuhura Biosciences, Inc./Nv outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

Tuhura Biosciences, Inc./Nv is a small-cap company with a market capitalization of $107M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its Current Ratio of 0.18x is the lowest of the 59 peers that report one.

For HURA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 30.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 1.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)

A free account shows the exact forecast, rating and rank of 3 tickers you follow, HURA included.

Follow HURA free
Price

HURA price chart and AI forecast

HURA
Cross-section · 2026-10-16

How HURA ranks among 5184 stocks

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Fundamentals · 2026-06-30

Tuhura Biosciences, Inc./Nv (HURA) fundamentals

Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.

Valuation & Market

MetricHURAIndustry medianRank
Market Cap $107M $11.72B 60/60
P/B Ratio 5.77x 7.27x 27/42
EPS $-0.14 – –
Book Value/Share $0.30 – –
FCF/Share $-0.22 – –

Profitability & Margins

MetricHURAIndustry medianRank
ROE -49.9% 7.7% 29/38
ROA -29.1% 2.1% 35/43

Financial Health

MetricHURAIndustry medianRank
Current Ratio 0.18x 3.05x 59/59
D/E Ratio 0.72x 1.23x 31/48
Financial Leverage 1.72x 2.09x 30/48
Working Capital -$8M $863M 53/59

Cash Flow

MetricHURAIndustry medianRank
Operating Cash Flow -$13M $166M 37/59
Free Cash Flow -$13M $148M 32/50
Capital Spending -$190K -$55M 2/50

Income Statement

MetricHURAIndustry medianRank
Net Income -$9M $28M 25/46
R&D Expense $7M $527M 58/58

Dividend & Shareholder Information

MetricHURAIndustry medianRank
Shares Outstanding 61M – –
Net Income Growth -331.2% 0.1% 19/19

Balance Sheet Highlights (USD millions)

Total Current Assets$2M5.2% of assets
Cash & Short-term Investments$1M3.1% of assets
Total Liabilities$13M41.7% of assets
Short-term Debt$6M19.5% of assets
Quarterly Financial Reports

HURA quarterly financials and insider trading

Industry Peers · Pharmaceutical Preparations

Tuhura Biosciences, Inc./Nv (HURA) industry peers

Companies classified under the same SEC industry code as Tuhura Biosciences, Inc./Nv (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Reveal all forecasts · See exact % predictions for all competitors

Sign up free
Company 90-Day AI Forecast (Alpha) Market Cap P/E Ratio P/B Ratio
HURA Tuhura Biosciences, Inc./Nv ▼ $107M – 5.8x
LLY Eli Lilly & Co ▶ $1.18T 42.2x 120.4x
JNJ Johnson & Johnson ▼ $615.87B 29.7x 7.3x
ABBV Abbvie Inc. ▶ $504.37B 73.8x –
MRK Merck & Co., Inc. ▲ $360.08B 116.8x 8.6x
NVS Novartis Ag ▼ $287.41B 9.0x –
AZN Astrazeneca Plc ▼ $256.39B 11.9x –
ABT Abbott Laboratories ▼ $182.39B 29.4x 3.5x
NVO Novo Nordisk A S ▼ $172.56B 2.9x –
PFE Pfizer Inc ▶ $168.60B 36.5x 2.0x
VRTX Vertex Pharmaceuticals Inc / Ma ▶ $126.66B 29.1x 6.3x
BMY Bristol Myers Squibb Co ▶ $122.05B 13.1x 5.5x
GSK Gsk Plc ▼ $100.46B 5.5x –
SNY Sanofi ▼ $100.12B – –
REGN Regeneron Pharmaceuticals, Inc. ▶ $81.76B 19.6x 2.6x
TAK Takeda Pharmaceutical Co Ltd ▼ $61.45B 5.9x –
TEVA Teva Pharmaceutical Industries Ltd ▼ $48.36B 86.5x 6.2x
ONC Beone Medicines Ltd. ▲ $41.96B 1272.7x 8.1x
ZTS Zoetis Inc. ▼ $32.80B 13.1x 10.4x
ALNY Alnylam Pharmaceuticals, Inc. ▶ $31.02B 58.3x 22.9x
RPRX Royalty Pharma Plc ▶ $26.88B 34.8x 3.9x
ROIV Roivant Sciences Ltd. ▲ $24.22B – 5.7x
GMAB Genmab A/S ▲ $23.80B 1.5x –
UTHR United Therapeutics Corp ▶ $22.87B 19.1x 3.6x
VTRS Viatris Inc ▼ $21.43B – –
INSM Insmed Inc ▶ $21.02B – 27.8x
ASND Ascendis Pharma A/S ▲ $14.85B – –
JAZZ Jazz Pharmaceuticals Plc ▼ $13.65B 14.4x 2.8x
BBIO Bridgebio Pharma, Inc. ▶ $12.98B – –
CORT Corcept Therapeutics Inc ▲ $11.91B 123.8x 16.9x
ELAN Elanco Animal Health Inc ▼ $11.77B – 1.8x
SMMT Summit Therapeutics Inc. ▶ $11.67B – 18.5x
RDY Dr Reddys Laboratories Ltd ▼ $10.91B 14.4x –
BMRN Biomarin Pharmaceutical Inc ▶ $10.58B 68.4x 1.7x
MDGL Madrigal Pharmaceuticals, Inc. ▶ $10.39B – 19.8x
CYTK Cytokinetics Inc ▲ $8.61B – –
TGTX Tg Therapeutics, Inc. ▲ $8.56B 20.4x 14.2x
PTGX Protagonist Therapeutics, Inc ▶ $8.33B 163.0x 9.9x
AXSM Axsome Therapeutics, Inc. ▲ $8.23B – 98.8x
ARWR Arrowhead Pharmaceuticals, Inc. ▲ $7.90B – 17.0x
ABVX Abivax S.A. ▼ $7.74B – –
IONS Ionis Pharmaceuticals Inc ▲ $7.14B – 16.2x
SYRE Spyre Therapeutics, Inc. ▲ $7.05B – 6.4x
ALKS Alkermes Plc. ▲ $6.92B 45.3x 3.8x
PRAX Praxis Precision Medicines, Inc. ▲ $6.75B – 5.0x
KNSA Kiniksa Pharmaceuticals International, Plc ▶ $6.13B 86.4x 10.1x
AMRX Amneal Pharmaceuticals, Inc. ▲ $6.13B 58.1x –
RYTM Rhythm Pharmaceuticals, Inc. ▲ $5.93B – 57.6x
LGND Ligand Pharmaceuticals Inc ▶ $5.89B 28.6x 6.1x
BLTE Belite Bio, Inc ▲ $5.62B – 7.3x
MIRM Mirum Pharmaceuticals, Inc. ▲ $5.20B – –
COGT Cogent Biosciences, Inc. ▶ $5.12B – 9.6x
PTCT Ptc Therapeutics, Inc. ▲ $4.94B – –
ORKA Oruka Therapeutics, Inc. ▲ $4.76B – 4.3x
ERAS Erasca, Inc. ▲ $4.68B – 12.9x
MANE Veradermics, Inc ▲ $4.55B – 5.6x
TVTX Travere Therapeutics, Inc. ▲ $4.44B – 181.0x
EWTX Edgewise Therapeutics, Inc. ▲ $4.04B – 9.0x
DNTH Dianthus Therapeutics, Inc. /De/ ▲ $4.03B – 3.4x
INDV Indivior Pharmaceuticals, Inc. ▶ $3.83B 13.1x –

Where HURA sits on the market map

Life Sciences · Pharmaceutical Preparations
Explore the map →
News

Tuhura Biosciences, Inc./Nv (HURA) stock news

Loading...

FAQ

Tuhura Biosciences, Inc./Nv (HURA) stock forecast FAQ

What is the Tuhura Biosciences, Inc./Nv (HURA) stock forecast?

Our AI ranks Tuhura Biosciences, Inc./Nv outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

How accurate are Tuhura Biosciences, Inc./Nv stock predictions?

For HURA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 30.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 1.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

How often are Tuhura Biosciences, Inc./Nv forecasts updated?

Tuhura Biosciences, Inc./Nv forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.

Which companies are Tuhura Biosciences, Inc./Nv's industry peers?

60 issuers in our coverage, HURA included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.